CRM vs MRK: Which Is the Better Buy?
Side-by-side comparison of Salesforce, Inc. and Merck & Co., Inc. — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-09-22.
Salesforce, Inc. · Technology
$236.42
+11.6% upside to fair value
Med Conviction
Grade B
High Quality
VS
Merck & Co., Inc. · Healthcare
$147.17
-4.1% upside to fair value
Med Conviction
Grade C
QuantHub Verdict
CRM has more upside to fair value
(+11.6%).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
CRM |
MRK |
| Current Price |
$236.42 |
$147.17 |
| Fair Value Estimate |
$263.88 |
$141.07 |
| Upside to Fair Value |
+11.6%
|
-4.1%
|
| Market Cap |
$193.6B |
$363.5B |
| Forward P/E |
—
|
—
|
| EV / EBITDA |
14.4x
|
29.6x
|
| Price / Sales |
4.4x
|
5.5x
|
| Price / FCF |
12.8x
|
22.6x
|
| Revenue Growth YoY |
+10.8%
|
+5.1%
|
| Gross Margin |
77.3%
|
75.4%
|
| Operating Margin |
21.4%
|
16.7%
|
| Return on Equity |
20.2%
|
6.6%
|
| Dividend Yield |
0.73% |
2.31% |
| FCF Yield |
7.82%
|
4.42%
|
| Analyst Consensus |
Buy
|
Buy
|
Investment Thesis
Salesforce is the leading enterprise customer relationship management platform, spanning Sales, Service, Platform, Marketing, Commerce, Tableau, MuleSoft, and Slack under the Customer 360 umbrella, with 83,334 employees and a business that converts $53.65 of revenue per share into $18.48 of free cash flow per share. Business quality is high: TTM gross margin of 77.3%, TTM operating margin of 21.4…
Merck & Co., Inc. is a global healthcare leader with two core divisions, Pharmaceuticals and Animal Health, spanning oncology, vaccines, acute hospital care, immunology, neuroscience, virology, cardiovascular and diabetes, and it employs roughly 74,000 people under CEO Robert Davis. The business quality is medium: TTM gross margin of 75.4% and TTM operating margin of 16.7% reflect a genuinely hig…
Accumulation Zones
| Metric |
CRM |
MRK |
| Zone Low |
$197.91 |
$105.80 |
| Zone High |
$224.30 |
$119.91 |
| In Buy Zone? |
No
|
No
|